MagneSensors’ nanotechnology platform utilizes patented ultra high sensitivity superconducting quantum interference device (SQUID) sensors to detect the magnetic field generated by magnetic nanoparticles that are attached to biological molecules of interest. The targeted biological molecules are recognized by either antibodies or nucleic acid probes that we coat onto the magnetic nanoparticle labels.
Magnetic detection is entirely different from existing optical and radioactive platforms, overcoming some inherent limitations in other platforms and providing breakthrough advantages.
We have performed thousands of different proof-of-concept magnetic assays over the past decade. These include cell assays (both cell surface receptor and intracellular), sandwich immunoassays assays for proteins, and more recently, sandwich hybridization assays for the direct detection of nucleic acids (no amplification).